NOTICE IS HEREBY GIVEN that the 20212022 annual meeting of stockholders of Tricida, Inc., a Delaware corporation, will be held on June 10, 2021,15, 2022, at 7:30 a.m. Pacific Daylight Time in a virtual meeting format only at www.virtualshareholdermeeting.com/TCDA2021TCDA2022.

During the annual meeting, stockholders will be asked to consider the following matters, as more fully described in the proxy statement accompanying this notice:

Stockholders of record at the close of business on April 14, 202118, 2022 are entitled to notice of, and to vote at, the annual meeting and any adjournment or postponement thereof. All stockholders are cordially invited to attend the meeting.

You may cast your vote over the Internet, by telephone, or by completing and mailing a proxy card. Returning the proxy does not deprive you of your right to attend the annual meeting and to vote your shares in person. Proxies forwarded by or for banks, brokers or other nominees should be returned as requested by them. We encourage you to vote promptly to ensure your vote is represented at the annual meeting, regardless of whether you plan to attend.

You can find detailed information regarding voting in the section entitled “General Information” on pages 1 through 45 of the accompanying proxy statement.

This proxy statement is furnished to stockholders of Tricida, Inc. (“we,” “us,” “our” or the “Company”), a Delaware corporation, in connection with the solicitation of proxies by our board of directors for use at our 20212022 annual meeting of stockholders to be held on June 10, 2021,15, 2022, and at any adjournment or postponement thereof. The annual meeting will be held at 7:30 a.m. Pacific Daylight Time in a virtual meeting format only at www.virtualshareholdermeeting.com/TCDA2021TCDA2022.

As permitted by the rules of the Securities and Exchange Commission, or SEC, we are making this proxy statement and its Annual Report on Form 10-K for the fiscal year ended December 31, 20202021 available to our stockholders electronically via the Internet at www.proxyvote.com. You will be asked to enter the 16-digit control number located on your proxy card or Notice of Internet Availability of Proxy Materials (“Internet Notice”). On or about April 27, 2021,26, 2022, we mailed to our stockholders the Internet Notice, containing instructions on how to access this proxy statement and vote online or by telephone. If you received an Internet Notice by mail, you will not receive a printed copy of the proxy materials in the mail unless you specifically request them pursuant to the instructions provided in the Internet Notice. The Internet Notice instructs you on how to access and review all of the important information contained in this proxy statement.

Please note that references to our website herein do not constitute incorporation by reference of the information contained at or available through our website.

We are distributing our proxy materials because our board of directors is soliciting your proxy to vote at the annual meeting. This proxy statement summarizes the information you need to vote at the annual meeting. You do not need to attend the annual meeting to vote your shares.

Pursuant to SEC rules, we are providing access to our proxy materials via the Internet. Accordingly, we are sending an Internet Notice to all of our stockholders as of the record date. All stockholders may access our proxy materials on the website referred to in the Internet Notice. You may also request to receive a printed set of the proxy materials. You can find instructions regarding how to access our proxy materials via the Internet and how to request a printed copy in the Internet Notice. Additionally, by following the instructions in the Internet Notice, you may request to receive proxy materials in printed form by mail or electronically by email on an ongoing basis. We believe that these rules allow us to provide our stockholders with the information they need while lowering the costs of delivery and reducing the environmental impact of the annual meeting.

The proposals to be voted on at the annual meeting and the board of directors recommendation on each proposal is set forth below:

You may change your vote or revoke your proxy at any time before it is voted at the annual meeting. If you are a stockholder of record, you may change your vote or revoke your proxy by:

If your shares are held in the name of a bank, broker or other nominee, you may change your vote by submitting new voting instructions to your bank, broker or other nominee. Please note that if your shares are held of record by a bank, broker or other nominee, and you decide to attend and vote at the annual meeting, your vote at the annual meeting will not be effective unless you present a legal proxy, issued in your name from the record holder (your bank, broker or other nominee).

To ensure that proxies are received in time to be counted prior to the annual meeting, proxies submitted by Internet or by telephone should be received by 11:59 p.m. Eastern Daylight Time on the day before the annual meeting, and proxies submitted by mail should be received by the close of business on the day prior to the date of the annual meeting.

If you share an address with another stockholder and receive only one set of proxy materials but would like to request a separate copy of these materials, please contact our mailing agent, Broadridge at www.proxyvote.com, by telephone at 1-800-579-1639 or by email at: sendmaterial@proxyvote.com. Similarly, you may also contact Broadridge if you receive multiple copies of the proxy materials and would prefer to receive a single copy in the future. If you own shares through a bank, broker, or other nominee, you should contact the nominee concerning householding procedures.

Our board of directors currently consists of seven (7) directors, which are divided into three classes with staggered, three-year terms. Our bylaws provide that our board of directors will consist of not less than seven (7) and not more than twelve (12) directors. At the annual meeting, our stockholders will elect threetwo Class IIII directors, whose terms will expire at the annual meeting of stockholders to be held in 2024.2025. Each of our current directors continues to serve as a director until the election and qualification of his or her successor, or until his or her earlier death, resignation or removal.

Our board of directors nominated each of Ms. Kathryn Falberg, Dr. Gerrit KlaernerSandra Coufal and Dr. Klaus VeitingerDavid Hirsch for election to our board of directors as Class IIII directors at the annual meeting. All threeBoth nominees currently serve on our board of directors and have consented to be named in this proxy statement. Each nominee has agreed to serve as a director, if elected, until the 20242025 annual meeting of stockholders and until their successors have been duly elected and qualified or until their earlier resignation or removal.

The following table sets forth information with respect to our directors, including the threetwo nominees for election at the annual meeting:

Additional biographical descriptions of the nominees and continuing directors are set forth in the text below. These descriptions include the experience, qualifications, qualities and skills that led to the conclusion that each director should serve as a member of our board of directors at this time.

Nasdaq rules require that independent directors comprise a majority of a listed company’s board of directors. In addition, Nasdaq rules require that, subject to specified exceptions, each member of a listed company’s audit, compensation and corporate governance and nominating committees be independent. Our board of directors has determined that Dr. Klaus Veitinger, Dr. Robert Alpern, Dr. David Bonita, Dr. Sandra Coufal, Ms. Kathryn Falberg and Dr. David Hirsch qualify as “independent” directors in accordance with the Nasdaq listing requirements. Dr. Gerrit Klaerner is not independent due to his role as Chief Executive Officer and President of the Company. The Nasdaq independence definition includes a series of objective tests, such as that the director is not, and has not been for at least three years, one of our employees and that neither the director nor any of his family members has engaged in various types of business dealings with us. In addition, as required by Nasdaq rules, our board of directors has made a subjective determination as to each independent director that no relationships exist which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In making these determinations, our board of directors reviewed and discussed information provided by the directors and us with regard to each director’s business and personal activities and relationships as they may relate to us and our management. There are no family relationships among any of our directors or executive officers.

Our amended and restated bylaws and corporate governance guidelines provide our board of directors with flexibility to combine or separate the positions of Chairman of the Board and Chief Executive Officer and/or the implementation of a lead director in accordance with its determination that utilizing one or the other structure would be in the best interests of our Company. Dr. Klaus Veitinger currently serves as our Chairman of the Board.

As a general policy, our board of directors believes that separation of the positions of Chairman of the Board and Chief Executive Officer reinforces the independence of our board of directors from management, creates an environment that encourages objective oversight of management’s performance and enhances the effectiveness of our board of directors as a whole. As such, Dr. Gerrit Klaerner serves as our Chief Executive Officer and President while Dr. Klaus Veitinger serves as our Chairman of the Board but is not an officer of our Company. Our board of directors has concluded that our current leadership structure is appropriate at this time. However, our board of directors continues to periodically review our leadership structure and may make such changes in the future as it deems appropriate.

Our board of directors takes an enterprise-wide approach to risk management that seeks to complement our organizational objectives, strategic objectives, long-term organizational performance and the overall enhancement of stockholder value. Our board of directors assesses and considers the risks we face on an ongoing basis, including risks that are associated with our financial position, our competitive position and the impact of our operations on our cost structure. In addition, our board of directors reviews and assesses information regarding cybersecurity risks with management, including regular cybersecurity updates on cyber-attacks; Company-wide cyber awareness training targeting 12 training modules annually and internal phish testing, the results of which are generally reported to the audit committee;testing; and an annual cybersecurity audit including internal and external penetration testing performed by a third party in the fourth quarter of each year.year, the results of which are reported to the audit committee. Our board of directors’ approach to risk management includes understanding the risks we face, analyzing them with the latest information available and determining the steps that should be taken to manage those risks, with a view toward the appropriate level of risk for a company of our size and financial condition.

Certain committees of our board of directors actively manage risk within their given purview and authority. Our audit committee has the responsibility for overseeing our major financial, legal, and regulatory risk exposures, which span a variety of areas including litigation, regulatory compliance, reputational and policy matters, financial reporting and cybersecurity. Our audit committee also oversees the steps our management has taken to monitor and control these exposures, including policies and procedures for assessing and managing risk and related compliance efforts. Our compensation committee evaluates risks arising from compensation policies

The board of directors evaluates its performance and the performance of its committees and individual directors on an annual basis through an evaluation process administered by the nominating and corporate governance committee. The board of directors discusses each evaluation to determine what, if any, actions should be taken to improve the effectiveness of the board of directors or any committee thereof or of the directors.

Our board of directors held 913 meetings during the year ended December 31, 2020.2021. During 2020,2021, each person currently serving as a director attended at least 80%75% of the aggregate of the total number of meetings of the board of directors and each committee of which he or she was a member. Each director is also encouraged and expected to attend the Company’s annual meeting. All of our directors attended the 20202021 annual meeting of stockholders.

Our board of directors has established three standing committees: audit committee, compensation committee and nominating and corporate governance committee. Each committee operates pursuant to a written charter that has been approved by our board of directors. A copy of the current charter for each of the audit committee, compensation committee and nominating and corporate governance committee is available on our website at www.tricida.com by selecting the “Investors” link and then the “Governance” link. The audit committee met 46 times in 2020,2021, the compensation committee met 510 times in 20202021 and the nominating and corporate governance committee met oncetwice in 2020.2021.

Our board of directors has an audit committee and our board of directors has adopted an audit committee charter, which defines the audit committee’s principal functions, including oversight related to:

All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and Nasdaq. Our board of directors has determined that Ms. Falberg is an audit committee financial expert as defined under the applicable rules of the SEC and has the requisite financial sophistication as defined under the applicable rules and regulations of Nasdaq. Under the rules of the SEC and Nasdaq, members of the audit committee must also meet heightened independence standards. Our board of directors has determined that each of Dr. Bonita, Dr. Hirsch and Ms. Falberg are independent under these heightened audit committee independence standards. The audit committee operates under a written charter that satisfies the applicable standards of the SEC and Nasdaq.

Our board of directors has a compensation committee and our board of directors has adopted a compensation committee charter, which defines the compensation committee’s principal functions, including recommending policies relating to compensation and benefits of our directors, officers and employees. Among other matters, the compensation committee reviews and approves corporate goals and objectives relevant to compensation of our Chief Executive Officer, evaluateevaluates the performance of our Chief Executive Officer in light of those goals and objectives and approves the compensation of the Chief Executive Officer based on such evaluations. The compensation committee also recommends to our board of directorsapproves the issuance of stock options and other awards under our stock plans. Each of the members of our compensation committee has been determined to be independent under the applicable rules and regulations of Nasdaq, after considering the additional factors relevant to the independence of compensation committee members under the applicable standards of the SEC and Nasdaq, and is a “non-employee director” as defined in Rule 16b-3 promulgated under the Exchange Act. The compensation committee operates under a written charter that satisfies the applicable standards of the SEC and Nasdaq. The compensation committee may form and delegate authority to subcommittees consisting of one or more members when it deems appropriate.

Our board of directors has a nominating and corporate governance committee and our board of directors has adopted a nominating and corporate governance committee charter. The nominating and corporate governance committee is responsible for making recommendations to our board of directors regarding candidates for directorships and the size and composition of our board of directors and any of its committees. Among other matters, the nominating and corporate governance committee is responsible for developing and monitoring compliance with our corporate governance guidelines and reporting and making recommendations to our board of directors concerning governance matters. The nominating and corporate governance committee oversees the annual board evaluation process. Each of the members of our nominating and corporate governance committee is an independent director under the applicable rules and regulations of Nasdaq relating to nominating and corporate governance committee independence. The nominating and corporate governance committee operates under a written charter that satisfies the applicable standards of the SEC and Nasdaq.

In the process of identifying, screening and recommending director candidates to the full board of directors, the nominating and corporate governance committee takes into consideration the needs of the board of directors

During the year ended December 31, 2020,2021, none of the members of our compensation committee has, at any time, been one of our officers or employees. None of our executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee (or other board of directors committee performing equivalent functions or, in the absence of any such committee, the entire board of directors) of any entity that has one or more executive officers on our board of directors or compensation committee.

The board of directors has adopted our Corporate Governance Guidelines which provide the framework for our corporate governance along with our amended and restated certificate of incorporation, amended and restated bylaws, committee charters and other key governance practices and policies. Our Corporate Governance Guidelines cover a wide range of subjects, including the conduct of board meetings, independence and selection of directors, board membership criteria, and board committee composition. The Corporate Governance Guidelines are available on our website at www.tricida.com by selecting the “Investors” link and then the “Governance” link.

The board of directors has adopted our Code of Business Conduct and Ethics which applies to all of our employees, officers and directors, including those officers responsible for financial reporting. The Code of Business Conduct and Ethics is available on our website at www.tricida.com by selecting the “Investors” link and then the “Governance” link. Any amendments to the code, or any waivers of its requirements, will be disclosed on our website.

The board of directors believes that an ownership stake in the Company strengthens the alignment of interests between directors and stockholders. Accordingly, each director is required to own common stock (or equivalents) having a value of at least three times the annual retainer fee, within three years of becoming a

The Company has a policy that prohibits officers, directors and employees from engaging in hedging transactions, such as the purchase or sale of puts or calls, or the use of any other derivative instruments. Officers, directors and employees of the Company are also prohibited from holding Company securities in a margin account or pledging Company securities as collateral for a loan.

Any stockholder or other interested party who wishes to communicate with our board of directors or any individual director may send written communications to our board of directors or such director c/o Corporate Secretary, Tricida, Inc., 7000 Shoreline Court, Suite 201, South San Francisco, CA 94080. The communication

Our audit committee is responsible for reviewing and approving, prior to our entry into any such transaction, all related person transactions. In addition, our Code of Business Conduct and Ethics requires that our officers and employees avoid taking for themselves personally opportunities that are discovered through the use of our property, information or position or use of our property, information or position for personal gain. We have not adopted a separate written policy concerning the review, approval or ratification of related person transactions.

A related person transaction includes transactions in which:

A related person transaction does not include the compensation arrangements with our directors and executive officers that are described elsewhere in this proxy statement. ThereOther than as described below, there have not been any related person transactions since January 1, 2020.2021.

The following report of the compensation committee shall not be deemed to be “soliciting material” or to otherwise be considered “filed” with the SEC, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or the Securities Act, or the Securities Exchange Act of 1934, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference into such filing.

Our compensation committee has reviewed and discussed the section entitled “Compensation Discussion and Analysis” with our management. Based upon this review and discussion, the compensation committee recommended to the board of directors that the section entitled “Compensation Discussion and Analysis” be included in this proxy statement, andwhich was incorporated by reference into our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.2021.

This Compensation Discussion and Analysis contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements relate to expectations concerning matters that are not historical facts. Words such as “projects,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “may,” “will,” “could,” “should,” “would,” and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements related to risks associated with our compensation programs. Readers are cautioned that these forward-looking statements are based on current expectation and are subject to risks, uncertainties, and assumptions that are difficult to predict. We undertake no obligation to revise or update any forward-looking statements for any reason.

This Compensation Discussion and Analysis provides an overview of our executive compensation program for 20202021 and our executive compensation philosophies and objectives.

Our named executive officers consist of our Chief Executive Officer, our Chief Operating and Financial Officer, and our three other most highly compensated executive officers serving in such roles as of December 31, 2020 and one former executive officer of the Company who separated from the Company during 20202021 (collectively, the “Named Executive Officers”). For 2020,2021, our Named Executive Officers were:

Our current executive compensation program is intended to align executive compensation with our business objectives and to enable us to attract, retain and reward executive officers who contribute to our long-term success. We seek to accomplish this goal in a way that is aligned with the long-term interests of our stockholders. Our strategy has been to design the Company’s compensation programs to drive alignment of all

In 2021, we gained valuable clarity on the estimated timing of topline data from the VALOR-CKD trial. In August 2021, we submitted a VALOR-CKD trial protocol amendment that eliminated the first interim analysis for early stopping for efficacy after 150 primary endpoint events in order to preserve statistical and regulatory optionality for the trial. At this time, we also informed the FDA that there was a substantial likelihood that we would not have, or be able to obtain on reasonable terms in the allowancenecessary timeframe, adequate resources to continue the VALOR-CKD trial until we reach the current target of a U.S. patent application that, upon issuance in511 subjects with positively adjudicated primary endpoint events. In the fourth quarter of 2021, extended protection for veverimer to 2038 in the U.S.,we requested and the issuance of an additional 126 patents in 47 different countries, including Australia, China, Israel, Japan, Russia and numerous European and European extension states; and

The compensation paid or awarded to our executive officers is generally based on the assessment of each individual’s performance compared against the business objectives established for the fiscal year as well as our historical compensation practices. In the case of new hire executive officers, their compensation is primarily determined based on the negotiations of the parties as well as our historical compensation practices. In setting compensation, the Committeeour compensation committee of our board of directors (the “Committee”) also considers the competitive market, as discussed further below, and seeks to recognize and reward high performers through meaningful merit adjustments and bonus and equity incentive opportunities. As in prior years, for 2020,2021, the material elements of our executive compensation program were base salary, a cash incentive opportunity and equity-based compensation in the form of stock options. In addition, in September 2020,October 2021, the Committee approved acertain amendments to the 2020 retention program for all Company employees, including its Named Executive Officers, in order to motivate employees and to minimize employee departuresalign the retention program with the business objectives during the critical 2020 - 2021 time period for achievingcompletion of the VALOR-CKD trial and resubmission and approval of the Company’s NDA for veverimer and commercial launch. Each continuing employee ofAll Company employees employed at the

We value the opinions of our stockholders and engage with them on a variety of corporate governance matters to better understand their values, including with respect to the option exchange program that was approved by our stockholders in June 2021. The Company received approximately 99.7%80% support for its “say on pay” voteproposal at the Company’s 20202021 annual meeting of stockholders.stockholders on June 10, 2021. After considering these results, the Committee determined that the Company’s executive compensation philosophy, compensation objectives, and compensation elements continued to be appropriate and did not make any specific changes to the Company’s executive compensation program in response to the 20202021 “say on pay” vote.vote after consultation with its compensation consultant, Compensia, and due to the highly competitive biotechnology and pharmaceutical industries’ demand for talent.

Base salaries are intended to provide a level of compensation sufficient to attract and retain an effective management team, when considered in combination with the other components of our executive compensation program. The relative levels of base salary for our Named Executive Officers are evaluated against our peers in the industry and designed to reflect each executive officer’sNamed Executive Officer’s scope of responsibility and accountability with us. In 2020,The Company did not increase the Committee adjusted annual base salary levels based on a reviewsalaries of market data and individual performance. Mr. McKague’s base salary was determined when he joinedany of the Company based on a review of market data as well as the Company’s historical compensation practices.Named Executive Officers in 2021.

The table below sets forth the 20192020 and 20202021 base salary level for each of our Named Executive Officers:

The Committee undertakes a rigorous review and analysis to establish Company-wide performance goals under the AIP. ForAIP, which typically relate to the Company’s core operational areas, such as (i) clinical activities, (ii) regulatory affairs, (iii) technical operations and (iv) financial and corporate activities. As described in the AIP, for each Named Executive Officer other than Dr. Klaerner, 50% of his or her 2020payout under the AIP target wasis to be based on a qualitative assessment of individual performance and 50% wasis to be based on achievement of Company-wide performance goals relating to (i) regulatory developments, (ii) commercial operations, (iii) clinical activities, (iv) technical operations and (v) financial activities.approved by the board of directors. Dr. Klaerner’s entire 2020payout under the AIP target wasis to be based on the level of achievement of the Company-wide performance goals. For 2020,2021, the Committee established the following performance goals and weightings under the AIP with respect to the Company-wide performance goals. The performance goals were designed to be achievable, but required the coordinated, cross-functional focus and effort of the executives.executive officers.

As previously disclosed, in August 2020,In 2021, the Committee assessed performance against each of the Company-wide performance goals described above and determined that the Company receivedmade significant progress against the 2021 goals, with the exception of the goal related to NDA resubmission. Further, the Committee noted that the Company’s leadership team performed extremely well in a CRLchallenging business environment, helping to create significant value for our stockholders in 2021. In particular, the Committee considered the successful execution of the VALOR-CKD trial, including study subject retention and completion of randomization, clarity on the estimated timing of topline data from the FDA relatedVALOR-CKD trial pursuant to an administrative stop, the Company’s NDA for veverimer. The resulting delay in regulatory approval also impacted the goals associated with commercialization and profitability. The timeline for completion of enrollmentclosing of the ongoingregistered direct financing which secured capital through the VALOR-CKD trial was extended beyonddata readout in 2022 and the endsuccessful renegotiation of 2020. Accordingly, management recommendedour commercial manufacturing agreement to preserve capital resources. Considering all of these factors and the collective performance of the leadership team, the Committee determined that 2020an individual payout under the AIP would not fundin an amount equivalent to an overall attainment level of 75% for each of the Named Executive Officers was warranted, which was based on an assessment of Company-wide and accordingly, noneindividual performance.

The table below sets forth the AIP bonus targets and payouts to each of our Named Executive Officers received a payout under the 2020 AIP.based upon 2021 performance:

To further align the interests of our executive officers, including our Named Executive Officers, with the interests of our stockholders and to further focus our executive officers on our long-term performance, we have historically granted equity compensation in the form of stock options. The 20202021 equity grantsawards were determined based on individual performance, input of the

During 2020,2021, the Named Executive Officers were each participants in the Tricida, Inc. Executive Severance Benefit Plan, as amended, or the Executive Severance Plan, which provides severance payments and benefits upon certain qualifying terminations of employment with the Company, including in connection with a change in control of the Company. The Committee believes that these severance payments and benefits help secure the continued employment and dedication of our Named Executive Officers and are important as a recruitment and retention device, as many of the companies with which we compete for executive talent have similar arrangements in place for their senior management. The terms of the severance benefitsExecutive Severance Plan were determined based on a review of market practices and the input of the Committee’s independent compensation consultant, Compensia, and, consistent with market practices, do not include change in control-related tax gross-ups.

Our Named Executive Officers participate in our corporate-wide health and welfare benefit programs. Our Named Executive Officers are offered benefits that generally are commensurate with the benefits provided to all of our full-time employee, which includes participation in our qualified defined contribution plan. We do not provide perquisites that are often provided at other companies to executive officers.

The Committee is responsible for determining the compensation of our Chief Executive Officer and each of our other executive officers. In setting the compensation of our Chief Executive Officer, the Committee takes into account the nominating and corporate governance committee’s review of the Chief Executive Officer’s performance.performance against the goals and objectives set for the Company. In setting the compensation of our other executive officers, the Committee takes into account the Chief Executive Officer’s review of each executive officer’s performance and his recommendations with respect to their compensation. The Committee’s responsibilities regarding executive compensation are further described in the “Corporate Governance” section of this proxy statement.

Compensia is engaged at the sole discretion of the Committee to provide executive compensation consulting services. With respect to 2020,2021, Compensia provided services related to the review of 20202021 compensation adjustments, including a review of peer group compensation data, awards under our equity incentive program, the setting of performance goals in our annual incentive plan,Annual Incentive Plan and the related bonus targets, an analysis of the relationship between the Company’s pay and performance relative to peers, trends and tax and regulatory developments with respect to executive

In selecting companies for our peer group, the Committee considers recommendations from Compensia. The Committee approved the following peer group of companies to evaluate 20202021 executive compensation decisions: AcceleronAlbireo Pharma; Aimmune Therapeutics; Arena Pharmaceuticals; Biohaven Pharmaceutical;Alector; Ardelyx; Cara Therapeutics; ChemoCentryx; Chimerix; CorMedix; CymaBay Therapeutics; Cytokinetics; DecipheraEiger BioPharmaceuticals; G1 Therapeutics; GlycoMimetics; IVERIC bio; Mirum Pharmaceuticals; Epizyme; EsperionOvid Therapeutics; FibroGen; Global Blood Therapeutics; Iovance Biotherapeutics; Karyopharm Therapeutics; MyoKardia; Reata Pharmaceuticals;Oyster Point Pharma; Rhythm Pharmaceutical; Xencor;Spectrum Pharmaceuticals; and Zogenix. This is the same peer group that was used for evaluating 2019 compensation decisions, except Alder BioPharmaceuticals was removed due to its acquisition,Spero Therapeutics.

Albireo Pharma; Alector; Ardelyx; Chimerix; CorMedix; CymaBay Therapeutics; Eiger BioPharmaceuticals; G1 Therapeutics; GlycoMimetics; IVERIC bio; Mirum Pharmaceuticals; Ovid Therapeutics; Oyster Point Pharma; Spectrum Pharmaceuticals; and ImmunoGen, MacroGenics and Retrophin were removed due to low market capitalization and Cytokinetics, Epizyme, FibroGen and Iovance BiotherapeuticsSpero Therapeutics were added in order to better align the Company to industry peers with similar market capitalization. Aimmune Therapeutics was removed due to its acquisition, Acceleron Pharma; Arena Pharmaceuticals; Biohaven Pharmaceutical; Deciphera Pharmaceuticals; FibroGen; Global Blood Therapeutics; Iovance Biotherapeutics; MyoKardia; Reata Pharmaceuticals; and Xencor were removed due to high market capitalization as compared to the Company. Epizyme; Esperion Therapeutics; Karyopharm Therapeutics; and Zogenix were removed due to their commercialization of marketed products.

We believe that the compensation practices of our 20202021 peer group provided usthe Committee with appropriate benchmarksreferences for evaluating the compensation of our Named Executive Officers for 20202021 because of the developmental, market and organizational characteristics we shared with the companies in our peer group. In comparing the Company’s executive compensation program to the peer group, the Committee generally seekssought to align cash compensation with the 50th percentile of the peer group and equity compensation with the 75th percentile of the peer group, with deviations to recognize and reward high performers.

The following table shows information regarding the compensation of our Named Executive Officers for services performed in the year ended December 31, 20202021 and, to the extent required by applicable SEC executive compensation disclosure rules, December 31, 20192020 and 2018.2019.

The following table provides information regarding the possible payouts to our Named Executive Officers in 20202021 under the AIP the Cash Retention Awards and the equity awards received by our Named Executive Officers in 20202021 under the Tricida, Inc. 2018 Equity Incentive Plan, or the 2018 Plan.